Skip to main content
NIH funding notice RFA-HL-20-007

Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed)

Closed on October 1, 2019.

Posted
June 4, 2019
Close date
October 1, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
5
5 new
Median first-year cost
$488,421
$2,562,429 in all
Institutions
5
5 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. BOSTON UNIVERSITY MEDICAL CAMPUS1
  2. MAYO CLINIC ROCHESTER1
  3. UNIVERSITY OF ALABAMA AT BIRMINGHAM1
  4. UNIVERSITY OF CALIFORNIA LOS ANGELES1
  5. UNIVERSITY OF PENNSYLVANIA1

Most frequent study sections

  1. Special Emphasis Panel (ZHL1 CSR-A (M1))5
5 awards under RFA-HL-20-007 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2021Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary Fibrosis1U01HL152970-01Beers, Michael FrancisUNIVERSITY OF PENNSYLVANIA, PAFirst-year cost $616,340Study section ZHL1
FY2021Developing a patient-specific organoid model of pulmonary fibrosis using iPSCs1U01HL152976-01Kotton, Darrell N.BOSTON UNIVERSITY MEDICAL CAMPUS, MAFirst-year cost $508,550Study section ZHL1
FY2021Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis1U01HL153000-01Belperio, John ADamoiseaux, RobertGomperts, Brigitte NUNIVERSITY OF CALIFORNIA LOS ANGELES, CAFirst-year cost $488,421Study section ZHL1
FY2021Therapeutic ECM Resorption in Cellular Systems and Precision Cut Lung Slices.1U01HL152967-01Tschumperlin, Daniel J.MAYO CLINIC ROCHESTER, MNFirst-year cost $486,834Study section ZHL1
FY2021Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosis1U01HL152978-01Rowe, Steven MarkUNIVERSITY OF ALABAMA AT BIRMINGHAM, ALFirst-year cost $462,284Study section ZHL1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-HL-20-007: Advancing Novel Research Models to Study Idiopathic Pulmonary Fibrosis (U01 Clinical Trial Not Allowed) | ScienceDex | ConductScience